ATLANTA, GA – – (Globe Newswire – March 4, 2024) – – A shareholder class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX). The lawsuit alleges Defendants made materially false and misleading statements and/or failed to disclose material adverse information in its Offering Documents and throughout the Class Period regarding the Company’s business, operations, and prospects, including allegations that: (i) VTX958 was less effective in treating psoriasis than Defendants had led investors to believe; (ii) as a result, VTX958’s clinical and/or commercial prospects were overstated; (iii) accordingly, Ventyx had misrepresented its ability to develop and commercialize effective product candidates; and (iv) Ventyx’s post-IPO business prospects were thus inflated.

If you bought Ventyx shares pursuant and/or traceable to the October 21, 2021 IPO, or between October 21, 2021 and November 6, 2023, and suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at, by toll-free telephone at (888)-508-6832 or, you may visit the firm’s website at to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is April 30, 2024.

Registration Deadline

Lead Plaintiff Deadline Has Passed

April 30, 2024

Submit Your Information

Shares Purchased(Required)
Date of Shares Purchased
Number of Shares Acquired
Acquisition Price Per Share
Shares Sold
Date of Shares Sold
Number of Shares Sold
Selling Price Per Share